IPP Bureau
Pfizer drug candidate shows strong results in tough breast cancer study
By IPP Bureau - March 19, 2026
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
IIT Roorkee unveils cutting-edge molecular medicine facility
By IPP Bureau - March 19, 2026
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
Roche unveils massive AI factory to supercharge drug development
By IPP Bureau - March 19, 2026
The facility features 2,176 high-performance GPUs across the US and Europe
Alcon walks away from LENSAR deal after regulatory roadblock
By IPP Bureau - March 19, 2026
At the center of the collapse is opposition from the Federal Trade Commission
Trial milestone sparks hope for first long-term gastroparesis treatment
By IPP Bureau - March 19, 2026
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
Zydus and Torrent Pharma to co-market Semaglutide injection in India
By IPP Bureau - March 19, 2026
Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
Strides acquires generic brands from Sandoz to boost Africa business
By IPP Bureau - March 19, 2026
The initial consideration for the transaction is US$ 12 million
Mankind Pharma acquires Rivotril brand for India
By IPP Bureau - March 19, 2026
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students
By IPP Bureau - March 19, 2026
SPARK has extended its influence to an additional 9.47 million students worldwide
Lupin Manufacturing Solutions announces expansion of Dabhasa facility
By IPP Bureau - March 19, 2026
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
By IPP Bureau - March 18, 2026
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients
By IPP Bureau - March 18, 2026
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
PsiQuantum joins forces with Japan’s National Cancer Center to revolutionize cancer research with quantum computing
By IPP Bureau - March 18, 2026
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
Zydus, Lupin join forces to expand access to semaglutide in India
By IPP Bureau - March 18, 2026
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
